From five- to six-membered rings: 3,4-Diarylquinolinone as lead for novel p38MAP kinase inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 6, 2007, Pages 1213-1221

  Peifer, Christian ^a   Kinkel, Katrin ^a   Abadleh, Mohammed ^a   Schollmeyer, Dieter ^b   Laufer, Stefan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 FLUOROPHENYL) 4 PYRIDIN 4 YLQUINOLIN 2(1H) ONE; 4 [3 (4 FLUOROPHENYL) 5 ISOPROPYLISOXAZOL 4 YL]PYRIDINE; IMIDAZOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; MOLECULAR MODEL; PHARMACOPHORE; STRUCTURE ANALYSIS; X RAY ANALYSIS;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; MITOGEN-ACTIVATED PROTEIN KINASE 10; MODELS, MOLECULAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33947626488     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061097o     Document Type: Article

References (40)

1. Kung, C.; Shokat, K. M. Small-molecule kinase-inhibitor target assessment. ChemBioChem 2005, 6, 523-526.
2. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discovery 2002, 1, 727-730.
3. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1916.
4. Milanesi, L.; Petrillo, M.; Sepe, L.; Boccia, A.; D'Agostino, N.; Passamano, M.; Di Nardo, S.; Tasco, G.; Casadio, R.; Paolella, G. Systematic analysis of human kinase genes: a large number of genes and alternative splicing events result in functional and structural diversity. BMC Bioinformatics 2005, 6 Suppl 4, 20.
5. Daub, H. Characterization of kinase-selective inhibitors by chemical proteomics. Biochim. Biophys. Acta 2005, 1754, 183-190.
6. Luo, Y. Selectivity assessment of kinase inhibitors: Strategies and challenges. Curr. Opin. Mol. Ther. 2005, 7, 251-255.
7. Ortiz, A. R.; Gomez-Puertas, P.; Leo-Macias, A.; Lopez-Romero, P.; Lopez, V.; Morreale, A.; Murcia, M.; Wang, K. Computational approaches to model ligand selectivity in drug design. Curr. Top. Med. Chem. 2006, 6, 41-55.
8. Knight, Z. A.; Shokat, K. M. Features of selective kinase inhibitors. Chem. Biol. 2005, 12, 621-637.
9. Richards, M. L. Hot topic: New approaches to the treatment of inflammatory disorders. Curr. Top. Med. Chem. 2006, 6, 75.
10. McGovern, S. L.; Shoichet, B. K. Kinase inhibitors: Not just for kinases anymore. J. Med. Chem. 2003, 46, 1478-1483.
11. Boldt, S.; Kolch, W. Targeting MAPK signalling: Prometheus' fire or pandora's box? Curr. Pharm. Des. 2004, 10, 1885-1905.
12. Manning, A. M.; Davis, R. J. Targeting JNK for therapeutic benefit: From junk to gold? Nat. Rev. Drug Discovery 2003, 2, 554-565.
13. Johnson, G. L.; Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002, 298, 1911-1912.
14. (a) Choo, M. K.; Sakurai, H.; Koizumi, K.; Saiki, I. TAK1-mediated stress signaling pathways are essential for TNF-α-promoted pulmonary metastasis of murine colon cancer cells. Int. J. Cancer 2006, 118, 2758-2764.
15. (b) Argast, G. M.; Fausto, N.; Campbell, J. S. Inhibition of RIP2/RICK/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK. Mol. Cell. Biochem. 2005, 268, 129-140.
16. (c) Harper, S. J.; LoGrasso, P. Inhibitors of the JNK signaling pathway. Drugs Future 2001, 26, 957-973.
17. Goldstein, D. M.; Gabriel, T. Pathway to the clinic: Inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr. Top. Med. Chem. 2005, 5, 1017-1029.
18. (a) Lantos, I.; Bender, P. E.; Razgaitis, K. A.; Sutton, B. M.; DiMartino, M. J.; Griswold, D. E.; Walz, D. T. Antiinflammatory activity of 5,6-diaryl-2,3-dihydroimidazo[2,1-b]thiazoles. Isomeric 4-pyridyl and 4-substituted phenyl derivatives. J. Med. Chem. 1984, 27, 72-75.
19. (b) Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisa, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L.; Goldsmith, E. J. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6, 1117-1128.
20. Wagner, G.; Laufer, S. Small molecular anti-cytokine agents. Med. Res. Rev. 2006, 26, 1-62.
21. Peifer, C.; Wagner, G.; Laufer, S. New approaches to the treatment of inflammatory disorders by small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. 2006, 6, 113-149.
22. Fricker, M.; LoGrasso, P.; Ellis, S.; Wilkie, N.; Hunt, P.; Pollack, S. J. Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors. Arch. Biochem. Biophys. 2005, 438, 195-205.
23. Peifer, C.; Schollmeyer, D.; Laudage, S.; Laufer, S. 3-(4-Fluorophenyl)- 4-(4-pyridyl)quinolin-2(1H)-one. Acta Crystallogr., Sect. E: Struct. Rep. Online 2006, 62, 2475-2477.
24. Peifer, C.; Schollmeyer, D.; Selig, R.; Lauter, S. 4-(4-Fluorophenyl)-3- (4-pyridyl)quinolin-2(1H)-one. Acta Crystallogr., Sect. E: Struct. Rep. Online 2006, 62, 2648-2650.
25. Peifer, C.; Abadleh, M.; Schollmeyer, D. Laufer, S. 4-[3-(4-Fluorophenyl) -5-isopropylisoxazol-4-yl]pyridine. Acta. Crystallogr., Sect. E: Struct. Rep. Online 2006, 62, 3707-3709.
26. Peifer, C.; Abadleh, M.; Schollmeyer, D.; Laufer, S. 5-[(4-Fluorophenyl)- 3-isopropylisoxazol-4-yl]pyridine. Acta Crystallogr., Sect. E: Struct. Rep. Online 2006, 62, 3647-3649.
27. Laufer, S.; Thuma, S.; Peifer, C.; Greim, C.; Herweh, Y.; Albrecht, A.; Dehner, F. An immunosorbent, nonradioactive p38 MAP kinase assay comparable to standard radioactive liquid-phase assays. Anal. Biochem. 2005, 135-137.
28. Peifer, C.; Luik, S.; Thuma, S.; Herweh, Y.; Laufer, S. Development and optimization of a non-radioactive JNK3 assay. Comb. Chem. High Throughput Screening 2006, 9, 613-618.
29. Wagner, G. K. Pyridinyl-pyrimidine- und imidazole-Neue Hemmstoffe der Zytokinfreisetzung. Ph.D. Dissertation, Universität Tübingen, Tübingen, Germany, 2003.
30. McIntyre, C. J.; Ponticello, G. S.; Liverton, N. J.; O'Keefe, S. J.; O'Neill, E. A.; Pang, M.; Schwartz, C. D.; Claremon, D. A. Pyridazine based inhibitors of p38 MAPK. Bioorg. Med. Chem. Lett. 2002, 12, 689-692.
31. Kadnikov, D. V.; Larock, R. C. Synthesis of 2-quinolones via palladium-catalyzed carbonylative annulation of internal alkynes by N-substituted o-iodoanilines. J. Org. Chem. 2004, 69, 6772-6780.
32. Fürstner, A.; Hupperts, A. Carbonyl coupling reactions catalytic in titanium and the use of commercial titanium powder for organic synthesis. J. Am. Chem. Soc. 1995, 117, 4468-4475.
33. Cho, I. S.; Gong, L.; Muchowski, J. M. Synthesis of quinolines via ortho-lithiated N-acylanilines. A modified Friedlander synthesis. J. Org. Chem. 1991, 56, 7288-7291.
34. Chai, K. B.; Sampson, P. A convenient and efficient three-step synthesis of α-chloro keto acids. Tetrahedron Lett. 1992, 33, 585-588.
35. Marcaccini, S.; Pepino, R.; Pozo, M. C.; Basurto, S.; Valverde, M.; Torroba, T. One-pot synthesis of quinolin-2-(H)-ones via tandem Ugi-Knoevenagel condensations. Tetrahedron Lett 2004, 45, 3999-4001.
36. Rupert, K. C.; Henry, J. R.; Dodd, J. H.; Wadsworth, S. A.; Cavender, D. E.; Olini, G. C.; Fahmy, B.; Siekierka, J. J. Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. 2003, 13, 347-350.
37. Micetich, R. G.; Shaw, C. C.; Hall, T. W.; Spevak, P.; Fortier, R. A.; Wolfert, P.; Foster, B. C.; Bains, B. K. The 5-alkoxymethyl-, 5-alkylthiomethyl-, and 5-dialkylaminomethylisoxazoles. Heterocycles 1985, 23, 571-583.
38. Scapin, G. Structural biology in drug design: Selective protein kinase inhibitors. Drug Discovery Today 2002, 7, 601-611.
39. Trejo, A.; Arzeno, H.; Browner, M.; Chanda, S.; Cheng, S.; Comer, D. D.; Dalrymple, S. A.; Dunten, P.; Lafargue, J.; Lovejoy, B.; Freire-Moar, J.; Lim, J.; McIntosh, J.; Miller, J.; Papp, F.; Reuter, D.; Roberts, R.; Sanpablo, F.; Saunders, J.; Song, K.; Villasenor, A.; Warren, S. D.; Welch, M.; Weller, P.; Whiteley, P. E.; Zeng, L.; Goldstein, D. M. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase. J. Med. Chem. 2003, 46, 4702-4713.
40. Gill, A. L.; Frederickson, M.; Cleasby, A.; Woodhead, S. J.; Carr, M. G.; Woodhead, A. J.; Walker, M. T.; Congreve, M. S.; Devine, L. A.; Tisi, D.; O'Reilly, M.; Seavers, L. C.; Davis, D. J.; Curry, J.; Anthony, R.; Padova, A.; Murray, C. W.; Carr, R. A.; Jhoti, H. Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 2005, 48, 414-426.